AI's expansion into molecular engineering is a defining trend. Bio-AI startup Lemnisca recently secu...
The AMW Read
The article updates the player map for the Bio-AI vertical with Lemnisca's pre-seed round, signaling a shift from drug discovery toward biomanufacturing automation.
AI's expansion into molecular engineering is a defining trend. Bio-AI startup Lemnisca recently secured a pre-seed round, led by Theia Ventures, to scale its intelligent biomanufacturing systems, specifically focusing on optimizing fermentation. This move confirms AI's role is shifting from drug discovery to automating and optimizing the notoriously complex, slow, and resource-intensive bioproduction process itself. The global AI in biotechnology market is projected to hit $7.75 billion by 2029, a clear indicator that AI-driven process control is becoming a core competitive necessity for faster, more predictable, and more sustainable production of biological products and advanced therapies. This efficiency leap is crucial for scaling up the next generation of precision medicine.